Podocyte hypertrophy precedes apoptosis under experimental diabetic conditions

Apoptosis

Volumn 20, Issue 8, 2015, Pages 1056-1071

  Lee, Sun Ha ^a   Moon, Sung Jin ^b   Paeng, Jisun ^a   Kang, Hye Young ^a   Nam, Bo Young ^a   Kim, Seonghun ^a   Kim, Chan Ho ^a   Lee, Mi Jung ^a   Oh, Hyung Jung ^a   Park, Jung Tak ^a   Han, Seung Hyeok ^a   Yoo, Tae Hyun ^a   Kang, Shin Wook ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Catholic Kwandong University   (South Korea)

Author keywords

Apoptosis; Caspase; Diabetic nephropathy; Epidermal growth factor; Hypertrophy; Podocyte

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CASPASE 3; CASPASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; GLUCOSE; INITIATION FACTOR 4E BINDING PROTEIN 1; N ASPARTYL 2,6 DICHLOROBENZOYLOXYMETHYLKETONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; S6 KINASE; SYNAPTOPODIN; UNCLASSIFIED DRUG; WT1 PROTEIN; APOPTOSIS REGULATORY PROTEIN; ASPARTIC ACID; BENZYLOXYCARBONYL-ASP-CH2OC(O)-2,6-DICHLOROBENZENE; EGFR PROTEIN, RAT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL SIZE; CONTROLLED STUDY; DRUG EFFECT; FLUORESCENCE ACTIVATED CELL SORTING; GLOMERULUS; KIDNEY HYPERTROPHY; MALE; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; STREPTOZOTOCIN-INDUCED DIABETIC NEUROPATHY; TUNEL ASSAY; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION; HYPERTROPHY; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

EUKARYOTA; RATTUS;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ASPARTIC ACID; CASPASE 3; CASPASE INHIBITORS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION; HYPERTROPHY; KIDNEY GLOMERULUS; MALE; MICE; PODOCYTES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; STREPTOZOCIN;

EID: 84933182881     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-015-1134-0     Document Type: Article

References (61)

1. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, Kasiske B, Kutner N, Liu J, St Peter W, Guo H, Gustafson S, Heubner B, Lamb K, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Thompson B, Wang C, Weinhandl E, Zaun D, Arko C, Chen S, Daniels F, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers P, Agodoa L (2012) United states renal data system 2011 annual data report: atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 59(1 Suppl 1):A7, 1-420
2. Schrijvers BF, De Vriese AS, Flyvbjerg A (2004) From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25(6):971-1010
3. Leehey DJ, Singh AK, Alavi N, Singh R (2000) Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 77:S93-98
4. Hoffman BB, Sharma K, Ziyadeh FN (1998) Potential role of TGF-beta in diabetic nephropathy. Miner Electrolyte Metab 24(2-3):190-196
5. Baumgartl HJ, Sigl G, Banholzer P, Haslbeck M, Standl E (1998) On the prognosis of IDDM patients with large kidneys. Nephrol Dial Transplant 13(3):630-634
6. Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, Yoshinaga K (1993) The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 21(5):480-485
7. Ayo SH, Radnik RA, Glass WF, Garoni JA, Rampt ER, Appling DR, Kreisberg JI (1991) Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium. Am J Physiol 260:F185-191
8. Hostetter TH (2003) Hyperfiltration and glomerulosclerosis. Semin Nephrol 23(2):194-199
9. Wolf G (2004) New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 34(12):785-796
10. Osterby R (1992) Glomerular structural changes in type 1 (insulin-dependent) diabetes mellitus: causes, consequences, and prevention. Diabetologia 35(9):803-812
11. Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser WG, Seidel K (1995) Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 47(3):935-944
12. Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN (1992) High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-beta. Kidney Int 42(3):647-656
13. Wolf G (2000) Cell cycle regulation in diabetic nephropathy. Kidney Int Suppl 77:S59-66
14. Pavenstdt H, Kriz W, Kretzler M (2003) Cell biology of the glomerular podocyte. Physiol Rev 83(1):253-307
15. Barisoni L, Kriz W, Mundel P, D'Agati V (1999) The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 10(1):51-61
16. Nagata M, Hattori M, Hamano Y, Ito K, Saitoh K, Watanabe T (1998) Origin and phenotypic features of hyperplastic epithelial cells in collapsing glomerulopathy. Am J Kidney Dis 32(6):962-969
17. D'Agati V (1994) The many masks of focal segmental glomerulosclerosis. Kidney Int 46(4):1223-1241
18. Petermann AT, Pippin J, Durvasula R, Pichler R, Hiromura K, Monkawa T, Couser WG, Shankland SJ (2005) Mechanical stretch induces podocyte hypertrophy in vitro. Kidney Int 67(1):157-166
19. Xu Z, Yoo T, Ryu D, Park HC, Ha SK, Han DS, Adler SG, Natarajan R, Kang S (2005) Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli. Kidney Int 67(3):944-952
20. Saikumar P, Dong Z, Mikhailov V, Denton M, Weinberg JM, Venkatachalam MA (1999) Apoptosis: definition, mechanisms, and relevance to disease. Am J Med 107(5):489-506
21. Shimizu A, Masuda Y, Kitamura H, Ishizaki M, Sugisaki Y, Yamanaka N (1996) Apoptosis in progressive crescentic glomerulonephritis. Lab Invest 74(5):941-951
22. Kitamura H, Shimizu A, Masuda Y, Ishizaki M, Sugisaki Y, Yamanaka N (1998) Apoptosis in glomerular endothelial cells during the development of glomerulosclerosis in the remnant-kidney model. Exp Nephrol 6(4):328-336
23. Susztak K, Raff AC, Schiffer M, Bttinger EP (2006) Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55(1):225-233
24. Verzola D, Gandolfo MT, Ferrario F, Rastaldi MP, Villaggio B, Gianiorio F, Giannoni M, Rimoldi L, Lauria F, Miji M, Deferrari G, Garibotto G (2007) Apoptosis in the kidneys of patients with type II diabetic nephropathy. Kidney Int 72(10):1262-1272
25. Dalla Vestra M, Saller A, Mauer M, Fioretto P (2001) Role of mesangial expansion in the pathogenesis of diabetic nephropathy. J Nephrol 14(Suppl 4):S51-57
26. Mundel P, Shankland SJ (2002) Podocyte biology and response to injury. J Am Soc Nephrol 13(12):3005-3015
27. Marshall SM (2007) The podocyte: a potential therapeutic target in diabetic nephropathy? Curr Pharm Des 13(26):2713-2720
28. Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P (2003) Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 52(4):1031-1035
29. Jung D, Lee SH, Kwak S, Li JJ, Kim DH, Nam B, Kang HY, Chang TI, Park JT, Han SH, Yoo T, Kang S (2012) Apoptosis occurs differentially according to glomerular size in diabetic kidney disease. Nephrol Dial Transplant 27(1):259-266
30. Menini S, Iacobini C, Oddi G, Ricci C, Simonelli P, Fallucca S, Grattarola M, Pugliese F, Pesce C, Pugliese G (2007) Increased glomerular cell (podocyte) apoptosis in rats with streptozotocin-induced diabetes mellitus: role in the development of diabetic glomerular disease. Diabetologia 50(12):2591-2599
31. Herbach N, Schairer I, Blutke A, Kautz S, Siebert A, Göke B, Wolf E, Wanke R (2009) Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis. Am J Physiol Renal Physiol 296(4):F819-829
32. Kim DK, Nam BY, Li JJ, Park JT, Lee SH, Kim JY, Kang HY, Han SH, Yoo TH, Han DS, Kang SW (2012) Translationally controlled tumour protein is associated with podocyte hypertrophy in a mouse model of type 1 diabetes. Diabetologia 55(4):1205-1217
33. Mundel P, Reiser J, Zúñiga Mejía Borja A, Pavenstädt H, Davidson GR, Kriz W, Zeller R (1997) Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 236(1):248-258
34. Wassef L, Kelly DJ, Gilbert RE (2004) Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney Int 66(5):1805-1814
35. Chandrashekhar Y, Sen S, Anway R, Shuros A, Anand I (2004) Long-term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. J Am Coll Cardiol 43(2):295-301
36. Li B, Yao J, Kawamura K, Oyanagi Tanaka Y, Hoshiyama M, Morioka T, Gejyo F, Uchiyama M, Oite T (2004) Real-time observation of glomerular hemodynamic changes in diabetic rats: effects of insulin and ARB. Kidney Int 66(5):1939-1948
37. Kang SW, Adler SG, Nast CC, LaPage J, Gu JL, Nadler JL, Natarajan R (2001) 12-lipoxygenase is increased in glucose-stimulated mesangial cells and in experimental diabetic nephropathy. Kidney Int 59(4):1354-1362
38. Schwieger J, Fine LG (1990) Renal hypertrophy, growth factors, and nephropathy in diabetes mellitus. Semin Nephrol 10(3):242-253
39. Okada M, Takemura T, Yanagida H, Yoshioka K (2002) Response of mesangial cells to low-density lipoprotein and angiotensin II in diabetic (OLETF) rats. Kidney Int 61(1):113-124
40. Shankland SJ (2006) The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 69(12):2131-2147
41. Li JJ, Kwak SJ, Jung DS, Kim JJ, Yoo TH, Ryu DR, Han SH, Choi HY, Lee JE, Moon SJ, Kim DK, Han DS, Kang SW (2007) Podocyte biology in diabetic nephropathy. Kidney Int Suppl 72(106):S36-42
42. Seyer-Hansen K (1976) Renal hypertrophy in streptozotocin-diabetic rats. Clin Sci Mol Med Suppl 51(6):551-555
43. Rasch R, Nörgaard JO (1983) Renal enlargement: comparative autoradiographic studies of 3H-thymidine uptake in diabetic and uninephrectomized rats. Diabetologia 25(3):280-287
44. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A (1994) p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8(1):9-22
45. Ruster C, Bondeva T, Franke S, Forster M, Wolf G (2008) Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes. Nephrol Dial Transplant 23(7):2179-2191
46. Mori H, Inoki K, Masutani K, Wakabayashi Y, Komai K, Nakagawa R, Guan K, Yoshimura A (2009) The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem Biophys Res Commun 384(4):471-475
47. Sataranatarajan K, Mariappan M, Lee MJ, Feliers D, Choudhury GG, Barnes JL, Kasinath BS (2007) Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin. Am J Pathol 171(6):1733-1742
48. Sharma K, Ziyadeh FN (1997) Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. Semin Nephrol 17(2):80-92
49. Flannery PJ, Spurney RF (2006) Transactivation of the epidermal growth factor receptor by angiotensin II in glomerular podocytes. Nephron Exp Nephrol 103(3):e109-118
50. Gilbert RE, Cox A, McNally PG, Wu LL, Dziadek M, Cooper ME, Jerums G (1997) Increased epidermal growth factor in experimental diabetes related kidney growth in rats. Diabetologia 40(7):778-785
51. Advani A, Wiggins KJ, Cox AJ, Zhang Y, Gilbert RE, Kelly DJ (2011) Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy. Nephrology 16(6):573-581
52. Reidy K, Kang HM, Hostetter T, Susztak K (2014) Molecular mechanisms of diabetic kidney disease. J Clin Invest 124(6):2333-2340
53. Das S, Dey KK, Bharti R, MaitiChoudhury S, Maiti S, Mandal M (2012) PKI 166 induced redox signalling and apoptosis through activation of p53, MAP kinase and caspase pathway in epidermoid carcinoma. J Exp Ther Oncol 10(2):139-153
54. Fujimoto E, Yano T, Sato H, Hagiwara K, Yamasaki H, Shirai S, Fukumoto K, Hagiwara H, Negishi E, Ueno K (2005) Cytotoxic effect of the Her-2/Her-1 inhibitor PKI-166 on renal cancer cells expressing the connexin 32 gene. J Pharmacol Sci 97(2):294-298
55. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler IJ (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60(11):2926-2935
56. Franch HA, Shay JW, Alpern RJ, Preisig PA (1995) Involvement of pRB family in TGF beta-dependent epithelial cell hypertrophy. J Cell Biol 129(1):245-254
57. White KE, Bilous RW, Marshall SM, El Nahas M, Remuzzi G, Piras G, De Cosmo S, Viberti G (2002) Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 51(10):3083-3089
58. Gross ML, Ritz E, Schoof A, Adamczak M, Koch A, Tulp O, Parkman A, El Shakmak A, Szabo A, Amann K (2004) Comparison of renal morphology in the Streptozotocin and the SHR/N-cp models of diabetes. Lab Invest 84(4):452-464
59. Tunçdemir M, Oztürk M (2011) The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy. Acta Histochem 113(8):826-832
60. Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K, Hirakawa M, Taniguchi M, Masutani K, Iida M (2011) Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant 26(8):2475-2484
61. Peixoto EB, Papadimitriou A, Lopes de Faria JM (2012) Tempol reduces podocyte apoptosis via PARP signaling pathway in experimental diabetes mellitus. Nephron Exp Nephrol 120(2):e81-90.